Codexis Inc (CDXS) - Total Liabilities

Latest as of September 2025: $85.42 Million USD

Based on the latest financial reports, Codexis Inc (CDXS) has total liabilities worth $85.42 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Codexis Inc growing its equity to track the company's year-over-year net asset growth rate.

Codexis Inc - Total Liabilities Trend (2006–2024)

This chart illustrates how Codexis Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Codexis Inc to measure how efficiently the company converts operating cash flow to free cash.

Codexis Inc Competitors by Total Liabilities

The table below lists competitors of Codexis Inc ranked by their total liabilities.

Company Country Total Liabilities
Unique Optical Industrial Co Ltd
TWO:3441
Taiwan NT$253.09 Million
51Talk Online Education Group
NYSE MKT:COE
USA $97.35 Million
It's Skin Co Ltd
KO:226320
Korea ₩29.42 Billion
Deleum Bhd
KLSE:5132
Malaysia RM336.19 Million
PYRUM INNOV.AG NA O.N.
F:PYR
Germany €42.95 Million
Keyrus SA
PA:ALKEY
France €264.99 Million
Maxigen Biotech Inc
TW:1783
Taiwan NT$364.27 Million
Khonburi Sugar Public Company Limited
BK:KBS
Thailand ฿7.45 Billion

Liability Composition Analysis (2006–2024)

This chart breaks down Codexis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Codexis Inc stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.12 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.22 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.69 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Codexis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Codexis Inc (2006–2024)

The table below shows the annual total liabilities of Codexis Inc from 2006 to 2024.

Year Total Liabilities Change
2024-12-31 $82.08 Million +64.35%
2023-12-31 $49.95 Million -52.70%
2022-12-31 $105.60 Million +28.79%
2021-12-31 $81.99 Million +59.07%
2020-12-31 $51.54 Million +18.34%
2019-12-31 $43.56 Million +98.19%
2018-12-31 $21.98 Million -24.42%
2017-12-31 $29.08 Million +75.71%
2016-12-31 $16.55 Million -23.98%
2015-12-31 $21.77 Million -0.20%
2014-12-31 $21.81 Million +25.66%
2013-12-31 $17.36 Million -19.36%
2012-12-31 $21.52 Million -35.23%
2011-12-31 $33.23 Million -2.08%
2010-12-31 $33.94 Million -45.44%
2009-12-31 $62.20 Million -68.90%
2008-12-31 $200.01 Million -0.50%
2007-12-31 $201.01 Million +102.17%
2006-12-31 $99.42 Million --

About Codexis Inc

NASDAQ:CDXS USA Biotechnology
Market Cap
$129.16 Million
Market Cap Rank
#18736 Global
#4303 in USA
Share Price
$1.43
Change (1 day)
-1.38%
52-Week Range
$0.98 - $3.10
All Time High
$41.78
About

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more